AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04682197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset Research
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study NCT04639271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Plus And
Description: Pyrotinib::400mg/d,qd,po
Study NCT04639271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle
Study NCT04639271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 125mg/M2, qw iv
Study NCT04682197 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cereset Research
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study NCT05963880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)
Description: All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.
Study NCT05963880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)
Description: All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.
Study NCT05584059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Acceptance and Commitment Therapy
Description: This is an individual-based FACT counselling programme which composes of 4-6 sessions on a weekly basis (45-60mins/session). All the sessions are delivered by a trained FACT interventionist via either video-conferencing (e.g., Zoom or Windows Teams) or face-to-face format. The programme aims to increase the psychological flexibility of the parent, so that he/she is able to (i) experience the present moment and take perspective on self (i.e., Awareness); (ii) detach the distressing private experiences and associated rules and to take a non-judgemental, accepting stance toward the painful experiences (i.e., Openness) and (iii) exhibits strong connection with values and commit to values-consistent actions. The trained interventionist will use different ACT strategies in these sessions, including ACT metaphors, experiential exercises, guided mindfulness exercises, guided imagery exercises and values clarification exercises to reinforce the above principles.
Study NCT05272683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: On day 1 and day 8, participants will receive a single dose
Study NCT05272683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: On days 5 to 11, participants will receive itraconazole once daily
Study NCT06384066 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GetWell Mobile Application
Description: GetWell utilizes an interactive health care application to allow patients to participate in their care. We plan to work with GetWell to develop a custom built plan for urethroplasty patients and provide patient education.
Study NCT06384066 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Office Based Pathway
Study NCT06511973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen (BAYH006689)
Description: BAYH006689 gel will be dispensed directly on the patch
Study NCT06511973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo gel will be dispensed directly on the patch
Study NCT06511973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A solution of 0.9% Saline
Description: 0.9% Saline will be dispensed directly on the patch
Study NCT06511973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A solution of 0.2% SLS
Description: 0.2% SLS will be dispensed directly on the patch.
Study NCT06065488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ankle kinesio tap
Description: Kinesio Tape is popular among athletes and non-athletes for its ability to protect, support, and promote activity in overworked muscles. Few people are aware, however, that its healing benefits don't end there. Research studies show that taping ankle with Kinesio Tape actually improves ankle range of motion.
Study NCT06065488 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ankle kinesio tap
Description: Kinesio Tape is popular among athletes and non-athletes for its ability to protect, support, and promote activity in overworked muscles. Few people are aware, however, that its healing benefits don't end there. Research studies show that taping ankle with Kinesio Tape actually improves ankle range of motion.
Study NCT05163041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT7480
Description: Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
Study NCT05163041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
Study NCT05968274 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rebox-Physio 4 (real stimulation)
Description: Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.
Study NCT05968274 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rebox-Physio 4 (sham stimulation)
Description: In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded.
Study NCT05828862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypotension prediction index guidance
Description: using hypotension prediction index guidance to prevent intraoperative hypotension
Study NCT05972278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: 1 tablet daily
Study NCT05972278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obicetrapib
Description: 1 tablet daily
Study NCT05196828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTX100 Neuromodulation System
Description: Active Noninvasive peripheral nerve stimulation device programmed to active mode
Study NCT04595773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.
Study NCT04595773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercise Training
Description: Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.
Study NCT04595773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.
Study NCT04595773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.
Study NCT05478421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen sponge
Description: The bone cavity will be filled with collagen sponge.
Study NCT05478421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GBR
Description: The bone cavity will be applied with guided bone regeneration with deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
Study NCT05478421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CS/GBR
Description: The bone cavity will be applied with guided bone regeneration with collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
Study NCT05400317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-218
Description: PO, Once daily(QD), 12weeks
Study NCT05400317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-218A
Description: PO, Once daily(QD), 12weeks
Study NCT06034210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customised 3D-printed insoles
Description: Based on measurements from the 3D scanning procedure, and factoring in individual data such as age, weight, and activity preferences, custom insoles are designed using the ZOLA software. The insoles are then 3D-printed by Zoles ApS in Espergærde (Denmark), using BCN3D printers (Barcelona, Spain) and a TPU (Thermoplastic Polyurethane) filament material from Recreus (Alicante, Spain). The printed insoles are tailored for optimal support, performance, and comfort, with varying densities for areas like the arch and heel. They are finished with an OnSteam® microfiber cover for added durability and comfort. The insoles are intended for regular insertion into participants' shoes to align with their unique biomechanical needs. (Information translated and adapted from: https://www.zoles.eu/da/processen-bag-saalerne/)
Study NCT06045988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Contact Sleep Quality Monitor System
Description: Residents of long-term care facilities with Alzheimer's or other related dementias will utilize a sleep monitoring device for the four-week period they are involved in the study.
Study NCT06272799 — intervention group
Intervention type: DRUG
Intervention: T-DM1 adjuvant
Description: Evaluate the tolerability of treatment with adjuvant T-DM1 after failure to respond complete pathology to neoadjuvant treatment in terms of adverse events
Study NCT05673928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Given by IV (vein)
Study NCT05673928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given by PO
Study NCT06296953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PERIsign examination
Description: Patients will be examined with the new device, PERIsign
Study NCT06296953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PERIsign examination
Description: Patients will be examined with the new device, PERIsign
Study NCT04498221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging procedure
Description: During routine examination under anaesthetic 4 x peritumoural injection of investigator's choice of 99mTc-human albumin colloidal particles or Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
Study NCT04498221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical procedure
Description: Excision of contralateral nodes identified on imaging \*(fhSPECT or SPECT/CT\*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
Study NCT05705024 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells
Description: Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.
Study NCT05705024 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Solution
Description: For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.
Study NCT04765371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEXAMETHASONE
Description: Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
Study NCT04765371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREDNISOLONE
Description: Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
Study NCT06509659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Methacholine Challenge Test
Description: MCT with IOS alone versus MCT IOS and FEV1 combined
Study NCT06190093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg, intravitreal injection
Study NCT06190093 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg, intravitreal injection
Study NCT05992935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1403
Description: Sterile liquid for injection
Study NCT05992935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1405
Description: Sterile liquid for injection
Study NCT05992935 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT05992935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT04576507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Investigates two strengths of cannabis.
Study NCT06289751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10 mg/kg (body weight), 60 min, IV. Repeat every 3 weeks for a total of 3 cycles
Study NCT06289751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: 260 mg/m2 for 30 min. Repeat every 3 weeks for a total of 3 cycles.
Study NCT06289751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75-80 mg/m2, IV, 1 mg/min. Repeat every 3 weeks for a total of 3 cycles.
Study NCT06289751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrafascial hysterectomy
Description: Extrafascial hysterectomy + pelvic lymphadenectomy (or SLN mapping) (For participants who meet ConCerv criteria)
Study NCT06289751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy
Description: Radical hysterectomy + pelvic lymphadenectomy ± para-aortic lymphadenectomy (or SLN mapping) (For participants who do not meet ConCerv criteria)
Study NCT06289751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone biopsy
Description: Cold knife conization (CKC) (For participants with tumor size ≤2 cm after 3 cycles of chemo-immunotherapy)
Study NCT06175767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT101-5
Description: Tablet
Study NCT05011942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irrisept Irrigation solution
Description: ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects v. Normal saline irrigation will be used alone in control subjects at the same time points.
Study NCT05011942 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Irrisept Irrigation solution
Description: ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects v. Normal saline irrigation will be used alone in control subjects at the same time points.
Study NCT05748873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPVN06
Description: AAV-RdCVF-RdCVFL
Study NCT05512403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT with 18F-DOPA
Description: A 18F-FDOPA PET exam is then performed (acquisition of 30 minutes in List Mode format) according to the French guidelines for PET neuro-oncological indications (Verger et al. Med Nuc, 2020, (5)).~Patient preparation and acquisition:~* 4 hours of fasting~* No carbidopa premedication~* 2 MBq / kg of 18F-FDOPA~* Dynamic acquisition in List Mode format for 30 min starting simultaneously with the patient's injection~* Low dose scanner for attenuation correction
Study NCT04885569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with CBT (MICBT)
Description: The culturally adapted MICBT will include approaches of motivational interviewing and offer ways of managing difficulties from a cognitive behavioural formulation.
Study NCT04885569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based Relapse Prevention (MBRP)
Description: MBRP will incorporate cognitive-behavioural skills (i.e., effective coping skills, self-efficacy, and recognizing common antecedents of relapse) with mindfulness-based practices to decrease the probability of relapse by increasing awareness and flexible responding in the presence of substance use triggers.
Study NCT04885569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMIAB
Description: This will be integrated CBT based motivational interviewing plus mindfulness based relapse prevention intervention group.
Study NCT05334732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIS TALK Back Intervention
Description: The participants in this arm will be seen by a trained survivor coach and receive culturally tailored intervention materials.
Study NCT06199635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Forming Magnetic Anastomosis Device and Delivery System
Description: Self-Forming Magnetic Anastomosis Device to create a gastrointestinal anastomosis
Study NCT04982562 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 7T MRI
Description: Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
Study NCT05856500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: basic nutrition
Description: An adequate supply of energy and protein in diet, oral nutrition supplement or tube feeding enteral nutrition supplement when diet is deficient.
Study NCT05856500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral supplement of creatine and curcumin
Description: Creatine and curcumin are orally added other than basic nutrition treatment.